FDA Approves New Blood Test for Cancer Screening
Submitted by MAGA
Posted 51 days ago
FDA's Bold Move: New Blood Test for Colorectal Cancer Screening Brings Hope to Millions
In a groundbreaking decision, the U.S. Food and Drug Administration (FDA) has approved a revolutionary blood test called Shield for colorectal cancer screening in average-risk adults aged 45 and older.
This marks a significant step forward in cancer detection, as it introduces a less invasive, more accessible screening option that could save countless lives.
Developed by Guardant Health, this test enables healthcare providers to detect alterations associated with colorectal cancer through a simple blood draw, making the screening process far less daunting for patients.
Currently, approximately 70% of colorectal cancer deaths are preventable through early detection.
Yet, the American Cancer Society estimates that only around 60% of eligible Americans undergo screening as recommended.
"Shield represents an important milestone in our fight against cancer," said AmirAli Talasaz, co-CEO of Guardant Health. This sentiment is echoed by experts who believe this new test can bridge the existing screening gap, providing a fresh avenue for increased participation and earlier intervention.
The Shield test is designed for those at average risk for colorectal cancer, but it is expected to be a game changer in promoting routine screenings among those who may otherwise avoid traditional methods such as colonoscopies.
Clinical studies have shown that Shield has an impressive ability to identify existing cancers, reporting an accuracy rate on par with current stool-based testing options.
However, it does fall short when it comes to detecting precancerous lesions, a task that colonoscopies perform more effectively.
The FDA’s approval opens the door for broader insurance coverage, potentially alleviating the financial burden associated with similar laboratory-developed tests that have historically cost up to $895 for patients willing to self-pay.
Medical professionals believe that by offering a more favorable option, like a blood test, screening rates will rise, leading to earlier diagnoses and better treatment outcomes for more Americans.
This shift towards innovation in healthcare signals a promising future for colorectal cancer detection, aligning perfectly with the ongoing efforts to enhance patient care and accessibility.
As we celebrate this monumental leap forward in cancer screening, we must remain vigilant in advocating for advancements that prioritize patient needs and moral responsibility over bureaucratic red tape.
By championing initiatives that facilitate better healthcare solutions, we can pave the way for a healthier future for all Americans.
Sources:
cnn.com
newsnationnow.com
theepochtimes.com
In a groundbreaking decision, the U.S. Food and Drug Administration (FDA) has approved a revolutionary blood test called Shield for colorectal cancer screening in average-risk adults aged 45 and older.
This marks a significant step forward in cancer detection, as it introduces a less invasive, more accessible screening option that could save countless lives.
Developed by Guardant Health, this test enables healthcare providers to detect alterations associated with colorectal cancer through a simple blood draw, making the screening process far less daunting for patients.
Currently, approximately 70% of colorectal cancer deaths are preventable through early detection.
Yet, the American Cancer Society estimates that only around 60% of eligible Americans undergo screening as recommended.
"Shield represents an important milestone in our fight against cancer," said AmirAli Talasaz, co-CEO of Guardant Health. This sentiment is echoed by experts who believe this new test can bridge the existing screening gap, providing a fresh avenue for increased participation and earlier intervention.
The Shield test is designed for those at average risk for colorectal cancer, but it is expected to be a game changer in promoting routine screenings among those who may otherwise avoid traditional methods such as colonoscopies.
Clinical studies have shown that Shield has an impressive ability to identify existing cancers, reporting an accuracy rate on par with current stool-based testing options.
However, it does fall short when it comes to detecting precancerous lesions, a task that colonoscopies perform more effectively.
The FDA’s approval opens the door for broader insurance coverage, potentially alleviating the financial burden associated with similar laboratory-developed tests that have historically cost up to $895 for patients willing to self-pay.
Medical professionals believe that by offering a more favorable option, like a blood test, screening rates will rise, leading to earlier diagnoses and better treatment outcomes for more Americans.
This shift towards innovation in healthcare signals a promising future for colorectal cancer detection, aligning perfectly with the ongoing efforts to enhance patient care and accessibility.
As we celebrate this monumental leap forward in cancer screening, we must remain vigilant in advocating for advancements that prioritize patient needs and moral responsibility over bureaucratic red tape.
By championing initiatives that facilitate better healthcare solutions, we can pave the way for a healthier future for all Americans.
Sources:
cnn.com
newsnationnow.com
theepochtimes.com
Latest News